Free Trial
NASDAQ:ZVSA

ZyVersa Therapeutics Q3 2023 Earnings Report

ZyVersa Therapeutics logo
$0.12 -0.01 (-5.81%)
As of 08/29/2025 03:54 PM Eastern

ZyVersa Therapeutics EPS Results

Actual EPS
-$31.50
Consensus EPS
-$56.00
Beat/Miss
Beat by +$24.50
One Year Ago EPS
N/A

ZyVersa Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

ZyVersa Therapeutics Announcement Details

Quarter
Q3 2023
Time
N/A
Conference Call Date
Tuesday, November 14, 2023
Conference Call Time
7:00AM ET

Upcoming Earnings

ZyVersa Therapeutics' Q3 2025 earnings is scheduled for Thursday, November 13, 2025, with a conference call scheduled at 7:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Earnings Documents

ZyVersa Therapeutics Earnings Headlines

ZyVersa Therapeutics (NASDAQ:ZVSA) Trading Down 6.1% - Should You Sell?
Trump’s national nightmare is here
Porter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger the biggest forced rotation of capital since World War II. They reveal why Trump is mobilizing America’s tech giants… and name the two stocks most likely to soar as trillions shift behind the scenes.tc pixel
See More ZyVersa Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like ZyVersa Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on ZyVersa Therapeutics and other key companies, straight to your email.

About ZyVersa Therapeutics

ZyVersa Therapeutics (NASDAQ:ZVSA), a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. The company develops drug development platforms, including Cholesterol Efflux Mediator VAR 200, an injectable drug, which is in Phase 2a clinical trial to the treatment of renal indications, such as focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney diseases; and Inflammasome ASC Inhibitor IC 100, a humanized monoclonal antibody that is in preclinical stage for treatment of inflammatory diseases comprising acute respiratory syndrome, multiple sclerosis, IgA neuropathy, pancreatic cancer, Parkinson's and Huntington's disease, atherosclerosis, Alzheimer's disease, and obesity. ZyVersa Therapeutics, Inc. was founded in 2014 and is headquartered in Weston, Florida.

View ZyVersa Therapeutics Profile

More Earnings Resources from MarketBeat